Effect of Barnidipine on Blood Pressure and Serum Metabolic Parameters in Patients With Essential Hypertension: A Pilot Study

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Cardiovascular Pharmacology and Therapeutics

• Publication date

  2006-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/1074248406296108PMID 17220472
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impaired Capacity for Stimulated Fibrinolysis in Primary Hypertension Is Restored by Antihypertensive Therapy

  2006cited by this paper
• Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures.

  2006cited by this paper
• Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri

  2005cited by this paper
• Inflammation, atherosclerosis, and coronary artery disease.

  2005cited by this paper
• Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions.

  2005cited by this paper
• Clinical Outcomes in Antihypertensive Treatment of Type 2 Diabetes, Impaired Fasting Glucose Concentration, and Normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

  2005cited by this paper
• Barnidipine: a new calcium channel blocker for hypertension treatment

  2005cited by this paper
• Comparison of the Effects of Valsartan and Felodipine on Plasma Leptin and Insulin Sensitivity in Hypertensive Obese Patients

  2005cited by this paper
• Isoprostanes and other markers of peroxidation in atherosclerosis

  2005cited by this paper
• Thematic review series: The Immune System and Atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? Published, JLR Papers in Press, February 1, 2005. DOI 10.1194/jlr.R400017-JLR200

  2005cited by this paper
• Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome.

  2005cited by this paper
• Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

  2005cited by this paper
• Inflammation, atherosclerosis, and coronary artery disease.

  2005cited by this paper
• Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.

  2005cited by this paper
• Inhibition of oxidative stress and improvement of endothelial function by amlodipine in angiotensin II-infused rats.

  2004cited by this paper
• New Risk Factors for Atherosclerosis and Patient Risk Assessment

  2004cited by this paper
• Inflammation in Atherosclerosis and Implications for Therapy

  2004cited by this paper
• Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial.

  2004cited by this paper
• Effects of Antihypertensive and Hypolipidemic Drugs on Plasma and High-Density Lipoprotein-Associated Platelet Activating Factor-Acetylhydrolase Activity

  2004cited by this paper
• Amlodipine attenuates oxidative stress-induced hypertension.

  2004cited by this paper
• Guidelines for antihypertensive treatment: an update after the ALLHAT study.

  2004cited by this paper
• Old antihypertensives and new diabetes

  2004cited by this paper
• Alterations of Paraoxonase and Platelet-Activating Factor Acetylhydrolase Activities in Patients on Peritoneal Dialysis

  2004cited by this paper
• Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study.

  2004cited by this paper
• Role of oxidative stress in angiotensin-induced hypertension.

  2003influential reference
• Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis.

  2003cited by this paper
• Vascular responses in vivo to 8-epi PGF(2alpha) in normal and hypercholesterolemic pigs.

  2002cited by this paper
• Angiotensin II Type 1 Receptor Antagonism Improves Hypercholesterolemia-Associated Endothelial Dysfunction

  2002cited by this paper
• Fosinopril Versus Amlodipine Comparative Treatments Study: A Randomized Trial to Assess Effects on Plasminogen Activator Inhibitor-1

  2002cited by this paper
• Improvement of insulin sensitivity by a long-acting nifedipine preparation (nifedipine-CR) in patients with essential hypertension.

  2002cited by this paper
• Vascular responses in vivo to 8-epiPGF2α in normal and hypercholesterolemic pigs

  2002cited by this paper
• Increased Oxidative Stress in Experimental Renovascular Hypertension

  2001cited by this paper
• Barnidipine.

  2001cited by this paper
• State-of-the-Art lecture. Role of angiotensin and oxidative stress in essential hypertension.

  1999cited by this paper
• Effect of the Vasodilatory β-Blocker, Nipradilol, and Ca-Antagonist, Barnidipine, on Insulin Sensitivity in Patients with Essential Hypertension

  1998cited by this paper
• Effect of the vasodilatory beta-blocker, nipradilol, and Ca-antagonist, barnidipine, on insulin sensitivity in patients with essential hypertension.

  1998cited by this paper
• Two forms of vasoconstriction in systemic hypertension.

  1987cited by this paper

• Insights into the Pivotal Role of Calcium Channel Blockers and Its Nanoformulations in the Management of Hypertension

  2023cites this paper
• İnsan Serum Paraoksonaz-1 (hPON1) Üzerine Bendamustin İnhibisyon Etkisi

  2020cites this paper
• Potential Protective Role of Blood Pressure-Lowering Drugs on the Balance between Hemostasis and Fibrinolysis in Hypertensive Patients at Rest and During Exercise

  2019cites this paper
• Strategies to decrease oxidative stress biomarker levels in human medical conditions: A meta-analysis on 8-iso-prostaglandin F2α

  2018cites this paper
• Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus

  2016cites this paper
• Effect of bedtime dosing of barnidipine hydrochloride in non-dipper hypertensive patients with obstructive sleep apnoea not treated with continuous positive airway pressure.

  2016cites this paper
• Pharmacological Interactions of Paraoxonase 1 (PON1): A HDL-Bound Antiatherogenic Enzyme.

  2016cites this paper
• Olmesartan Combined With Amlodipine on Oxidative Stress Parameters in Type 2 Diabetics, Compared With Single Therapies

  2016cites this paper
• Human serum paraoxonase-1 (hPON1): in vitro inhibition effects of moxifloxacin hydrochloride, levofloxacin hemihidrate, cefepime hydrochloride, cefotaxime sodium and ceftizoxime sodium

  2015cites this paper
• Impact of antibacterial drugs on human serum paraoxonase-1 (hPON1) activity: an in vitro study.

  2014cites this paper
• Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia.

  2014cites this paper
• Inhibition Effects of Gemcitabine Hydrochloride, Acyclovir, and 5-Fluorouracil on Human Serum Paraoxonase-1 (hPON1): In Vitro

  2014cites this paper
• In vitro inhibitory effects of ofloxacin hydrochloride, ampicillin sodium, cefotaxime sodium, and ceftizoxime sodium on purified paraoxonase-1 (hPON1) from human serum

  2014cites this paper
• Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A2 (Lp-PLA2 ): a review

  2011cites this paper
• Dyslipidemia Induced by Drugs Used for the Prevention and Treatment of Vascular Diseases

  2011cites this paper
• Ezetimibe Treatment Lowers Indicators of Oxidative Stress in Hypercholesterolemic Subjects with High Oxidative Stress

  2011cites this paper
• Effects of barnidipine in comparison with hydrochlorothiazide on endothelial function, as assessed by flow mediated vasodilatation in hypertensive patients

  2011cites this paper
• Effect of antihypertensive treatment on circulating endothelial progenitor cells in patients with mild essential hypertension

  2011cites this paper
• The three-gene paraoxonase family: physiologic roles, actions and regulation.

  2011cites this paper
• The effect of antihypertensive agents on insulin sensitivity, lipids and haemostasis.

  2010cites this paper
• Effect of Cardiovascular Drugs on the Plasma Levels of Lipoprotein- Associated Phospholipase A 2 (Lp-PLA 2 )

  2010cites this paper
• Effect of Cardiovascular Drugs on the Plasma Levels of Lipoprotein- Associated Phospholipase A2 (Lp-PLA2)~!2009-10-29~!2009-12-28~!2010-04-08~!

  2010cites this paper
• Relationship among plasma secretory phospholipase A2, oxidized low density lipoprotein & paraoxonase activities in hypertensive subjects treated with angiotensin converting enzyme inhibitors.

  2009cites this paper
• Endothelial dysfunction is involved in lesion formation by the Relationship among plasma secretory phospholipase A 2 , oxidized low density lipoprotein & paraoxonase activities in hypertensive subjects treated with angiotensin converting enzyme inhibitors

  2009cites this paper
• Effects of barnidipine on blood pressure and left ventricular diastolic function in patients with hypertension and metabolic syndrome: A 12-week, open-label noncomparison study.

  2008cites this paper
• Effects of Eprosartan on Serum Metabolic Parameters in Patients with Essential Hypertension

  2007cites this paper